Google
Trusted Resources: News & Events
Latest announcements and gatherings
Sickle Cell Disease Association of America, Inc. and Hemanext® Inc. Form New Strategic Partnership
Sickle Cell Disease Association of America, Inc. (SCDAA) and Hemanext Inc., a privately held medical technology company dedicated to improving the quality, safety, efficacy and cost of red blood cell (RBC) transfusion therapy, are proud to announce a new partnership that will help SCDAA deliver on its mission and meet its goals. In 2020 Hemanext will collaborate with SCDAA on its educational programs, grassroots events and public-awareness campaigns.
Sickle cell disease (SCD) affects 100,000 individuals in the United States, disproportionately affecting African Americans with one in 500 African Americans suffering from the disease. People with SCD often require regular blood transfusions, particularly units of RBCs. Hemanext is committed to developing a novel RBC product to deliver improved and longer-lasting transfusions.
+myBinderRelated Content
-
What it’s like to be 17 and living with sickle cell diseaseTre Adegoroye is 17 and was diagnosed wi...
-
Sickle Cell Disease Stakeholder Engagement Workgroup—Strategies to Improve Sickle Cell Disease Primary CareThe Department of Health and Human Servi...
-
Red blood cell transfusion to treat or prevent complications in sickle cell disease: An overview of Cochrane reviewsBackground: Globally, sickle cell disea...
-
Hemoglobinopathy Counselor Training Course – VIRTUALUPDATE! 2020 Hemoglobinopathy Counselor ...
-
Global Alliance of Sickle Cell Disease OrganizationsGlobal Alliance of Sickle Cell Disease O...
-
Sickle Cell Advocacy and Management InitiativeSickle Cell Advocacy and Management Init...
-
A Britain’s Got Talent contestant revealed how she turned to singing following the death of her sonA Britain's Got Talent contestant whose ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.